Login to Your Account

Ambit Scraps IPO, Adds $30M in VC Round for AC220 Study

By Jennifer Boggs

Monday, June 13, 2011
Ambit Biosciences Inc.'s venture syndicate stepped up for a $30 million Series D-2 round to help support the ongoing Phase II pivotal trial of acute myeloid leukemia (AML) drug AC220 and allow the San Diego-based biotech to avoid the less-than-friendly initial public offering (IPO) market.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription